Actithera

#Actithera #AstraZeneca #Radiopharmaceuticals

Actithera appoints new CMO to advance radiopharmaceuticals 

Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer.  Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals.  Dalal… Read More

#News

#Actithera #Financing #Radioligand Therapies (RLTs) #Radiopharmaceuticals

Actithera raises $75.5m to support its precision radioligand therapies

Radiopharmaceutical biotech company Actithera has closed an oversubscribed $75.5 million Series A financing round.   The financing will support the advancement of Actithera’s lead fibroblast activation protein (FAP)-targeting asset into clinical development in multiple indications, while also enabling the continued development of its radioligand therapies (RLT) discovery platform… Read More

#Business & Investment #News